Recruiting

Acetylamantadine

Sponsor:

University of Manitoba

Code:

NCT02277938

Conditions

Cancer

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

Amantadine

Study Details

Brief summary:

Several factors discourage the implementation of cancer screening to the population in general, which would result in earlier diagnosis and an expected improved survival. Concurrent in vivo and in vitro research has shown that drug acetylation activity is increased in cancer. Amantadine may be of value in detecting the presence of cancer. Accordingly, this study will examine how Amantadine is eliminated by the body in cancer patients. This is an important step in validating a cancer detection method that can be implemented economically for screening of large numbers of people.

Conditions

Cancer

Study ID

NCT02277938

Start date

Aug, 2013

Status verified date

Mar, 2021

Completion date

Dec, 2021

Anticipated

Primary completion date

Dec, 2021

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Inclusion Criteria: newly diagnosed or untreated cancer (GI, lung, prostate and breast cancer)

-

Exclusion Criteria: Any previous adverse reaction to Amantadine

  • currently pregnant or lactating

Study Design

Enrollment

120 participants

Anticipated

Interventions and Outcome Measures

Arms

Amantadine

Lung cancer patients being prescribed chemotherapy

Interventions

Amantadine

Amantadine is a drug that has been on the market for several years and is currently approved for the treatment of Parkinson's disease and for prevention against influenza A infection. Amantadine may be of value in detecting the presence of cancer.

Primary outcome measure

  • Acetylated Amantadine levels in urine [ Time Frame: 2 and 4 hours after Amantadine ingestion ]

Central Contacts and Locations

Central contacts

Paramjit S Tappia, PhD

204-258-1230ptappia@sbrc.ca

Andrew Maksymiuk, MD

204-787-1884amaksymiuk@cancercare.mb.ca

Locations

St. Boniface Hospital

Recruiting

Winnipeg, Manitoba, Canada, R2H 2A6

Contacts

Paramjit S Tappia, PhD

204-258-1230ptappia@sbrc.ca

Andrew Maksymiuk, MD

204-7871884amaksymiuk@cancercare.mb.ca

More Information

Sponsor

University of Manitoba

Last update posted

Mar 17, 2021

Last verified

Mar, 2021

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by University of Manitoba on 2021-03-17.